Guardant360 CDx is the fastest, FDA-approved CGP panel with guideline-recommended biomarkers.1-4*

The market leader in liquid biopsy, backed by the strongest legacy in blood-based NGS.

First FDA-approved comprehensive liquid biopsy with results in 7 days.2†

References

Covered by Medicare for all advanced solid tumors.

For the complete intended use statement including companion diagnostic indications, please see the Guardant360 CDx Technical Information: Guardant360CDx.com/technicalinfo.

Trusted by more than 12,000 oncologists.

CGP, comprehensive genomic profiling; NGS, next-generation sequencing.
*Fastest refers to turnaround time based on Guardant Health data on file. 
†7-day turnaround time from sample receipt to results.